Paul Bisaro insider trades

Open-market stock purchases and sales by Paul Bisaro, Director at Myriad Genetics Inc, from SEC Form 4 filings since Jun 5, 2025.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +8%.

Recent trades

DateStockTradeValue
Jun 4, 2026MYGN Myriad Genetics IncBought (not open market)—
Jun 2, 2026NONE Keenova Therapeutics plcSold (not open market)—
Jun 2, 2026NONE Keenova Therapeutics plcSold (not open market)—
Jun 2, 2026NONE Keenova Therapeutics plcBought (not open market)—
May 14, 2026MYGN Myriad Genetics IncBought$27.6K
May 13, 2026ZTS Zoetis IncBought$152K
Feb 23, 2026 Keenova Therapeutics plcBought (not open market)—
Feb 19, 2026ZTS Zoetis IncBought (not open market)—
Feb 19, 2026ZTS Zoetis IncBought (not open market)—
Feb 18, 2026ZTS Zoetis IncBought (not open market)—
Jan 1, 2026 Keenova Therapeutics plcSold (not open market)—
Jan 1, 2026 Keenova Therapeutics plcSold (not open market)—
Jan 1, 2026 Keenova Therapeutics plcBought (not open market)—

Companies traded

  • MYGN Myriad Genetics Inc: 1 buy, last Jun 4, 2026
  • NONE Keenova Therapeutics plc: other filings, last Jun 2, 2026
  • ZTS Zoetis Inc: 1 buy, last May 13, 2026

Get free alerts when Paul Bisaro files a new trade →